Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Advanced Solid Tumors, Excluding Breast Cancer
Interventions
caffeine, diclofenac, omeprazole, midazolam, TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Kansas City, Kansas • Detroit, Michigan • Minneapolis, Minnesota + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

NCT06679413
Conditions
Healthy Study Participants
Interventions
midazolam, metformin, bupropion, fenfluramine HCl
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma, Melanoma
Interventions
ICI Therapy
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach

NCT03772262
Conditions
Interaction Drug Food
Interventions
goldenseal, Metformin, Furosemide, Midazolam oral solution, Rosuvastatin Oral Tablet
Dietary Supplement · Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Spokane, Washington
Conditions
Bacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria, Escherichia Coli
Interventions
Phage Therapy, Placebo
Drug · Other
Lead sponsor
Barbara Trautner
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Conditions
ACL Repair
Interventions
Cryoneurolysis
Procedure
Lead sponsor
Virtua Health, Inc.
Other
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Burlington, New Jersey • Cherry Hill, New Jersey
Conditions
Advanced Solid Tumor
Interventions
Sitravatinib, Warfarin, Dextromethorphan, Midazolam, Digoxin, Rosuvastatin, Nivolumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Goshen, Indiana • Austin, Texas • San Antonio, Texas + 2 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

NCT02401256
Conditions
Healthy
Interventions
Efavirenz, Bupropion, Rosuvastatin, Montelukast
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Osteoarthritis, Arthroplasty
Interventions
Ropivacaine with NaCl, Epinephrine, Morphine, Ketorolac Tromethamine, Ropivacaine
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Royal Oak, Michigan
Conditions
COVID-19
Interventions
IBI314, Placebo
Biological · Other
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
19
States / cities
Anaheim, California • Long Beach, California • San Diego, California + 12 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Voxelotor CYP and Transporter Cocktail Interaction Study

NCT05981365
Conditions
Sickle Cell Disease
Interventions
Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Post-operative Pain
Interventions
Dronabinol 2.5mg Cap, Placebo
Drug
Lead sponsor
Jeffrey L Gum MD
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Schizophrenia, Schizoaffective Disorder, Weight Gain
Interventions
H218O and 2H2O, administered as a mixed cocktail
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes

NCT01473888
Conditions
Stable Angina
Interventions
T89(Dantonic)
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV
Drug
Lead sponsor
Carl T. Hayden VA Medical Center
Federal
Eligibility
35 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Solid Tumor Malignancies
Interventions
ASA404, DMXAA, DXAA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Houston, Texas • Madison, Wisconsin
Conditions
Anxiety Disorders and Symptoms, Fibromyalgia, Arthritis, Chronic Pain, Hypertension,Essential
Interventions
IV Vitamin Infused Therapy Treatment, Herbal medicine
Dietary Supplement · Drug
Lead sponsor
Faith A. Richardson
Other
Eligibility
21 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dover, Delaware
Conditions
Glioblastoma Multiforme
Interventions
Combination Drug Therapy
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Cypress, California • Miami Springs, Florida • Durham, North Carolina
Conditions
Active Ulcerative Colitis
Interventions
Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Terminated Phase 4 Interventional Results available

UPMC OPTIMISE-C19 Trial, a COVID-19 Study

NCT04790786
Conditions
Covid19
Interventions
Lilly Bamlanivimab, Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab, Sotrovimab, Bebtelovimab
Biological
Lead sponsor
Erin McCreary
Other
Eligibility
12 Years to 120 Years
Enrollment
4,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Healthy Volunteers, Overweight, Obesity
Interventions
NNC9204-1177, Cocktail of 5 already approved drugs
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
Interventions
Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
1,394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With a Potential Alzheimer's Disease Compound

NCT00726726
Conditions
Alzheimer Disease
Interventions
Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey